Maxim analyst Anthony Vendetti lowered his price target on BioPharmX to $5 to reflect the share dilution from its share offering. The analyst is keeping his Buy rating on the stock however, having recently completed the enrollment in its 12-week Phase 2b clinical trial of BPX-04 for the treatment of rosacea.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.